hUCB
Phase 2Biologic
hUCB is one of 52 biologic programs targeting Cerebral Palsy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskPhase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
SGLT-2 Inhibitors
Novo NordiskPhase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
hUCB
SStemCyte Taiwan Co., Ltd.
Phase 2
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Tylenol
KKenvue Brands
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hUCB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SStemCyte Taiwan Co., Ltd.